{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:41:50Z","timestamp":1791423710212,"version":"4.3.3"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lastentautien Tutkimuss\u00e4\u00e4ti\u00f6"},{"name":"University of Helsinki"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat, was first reported in 1999 and linked to antibody formation. In 2021, localized lipoatrophy was observed in 14.5% of patients receiving daily rhGH, with repeated injections at the same sites being a common contributing factor. Long-acting rhGH (LAGH) preparation offers the advantage of weekly injections, enhancing patient comfort and adherence to treatment. Methods: This case report discusses a 5.5-year-old girl born at 40 weeks of gestation with a birth weight of 2300 g, diagnosed with idiopathic short stature and borderline GH secretion, along with a history of mild intrauterine growth retardation. Results: After initiating treatment with somatrogon, a non-pegylated fusion protein formulation of LAGH at the standard dose of 0.66 mg\/kg body weight weekly, administered by her family, she developed localized lipoatrophy at the injection site within eleven weeks. The injections were performed consistently in the same area of the right upper arm, where lipoatrophy emerged. Following the onset of this adverse effect, her treatment was adjusted to daily rhGH, with strict instructions to rotate injection sites. Despite these clear instructions, follow-up revealed that the parents continued to administer injections with the non-pegylated LAGH fusion protein formulation, this time in the left upper arm, leading to a recurrence of lipoatrophy within eight weeks. Conclusions: The recurrence underscores the importance of proper injection techniques, particularly site rotation, in preventing localized adverse effects. Given the limitations of this case, where the recommended adjustments were not followed by the parents, it is crucial to emphasize that the administration of the preparation should be discontinued immediately upon the appearance of side effects such as lipoatrophy. Individual reactions to drugs are always possible, and this highlights the need for clinician vigilance in monitoring and addressing adverse effects promptly during treatments with LAGH.<\/jats:p>","DOI":"10.3390\/children12010058","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:17:02Z","timestamp":1736155022000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone"],"prefix":"10.3390","volume":"12","author":[{"given":"Atilla","family":"B\u00fcy\u00fckgebiz","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Demiro\u011flu Bilim University, \u0130stanbul 34394, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-8834","authenticated-orcid":false,"given":"And","family":"Demir","sequence":"additional","affiliation":[{"name":"Pediatric Research Center, New Children\u2019s Hospital, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland"},{"name":"Department of Pediatrics, Faculty of Medicine, Dokuz Eyl\u00fcl University, \u0130zmir 35340, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106805","DOI":"10.1016\/j.phrs.2023.106805","article-title":"Efficacy, Safety, Quality of Life, Adherence and Cost-Effectiveness of Long-Acting Growth Hormone Replacement Therapy Compared to Daily Growth Hormone in Children with Growth Hormone Deficiency: A Systematic Review and Meta-Analysis","volume":"193","author":"Mameli","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/JPEM.1999.12.1.95","article-title":"Localized Lipoatrophy Due to Recombinant Growth Hormone Therapy in a Child with 6.7 Kilobase Gene Deletion Isolated Growth Hormone Deficiency","volume":"12","author":"Buyukgebiz","year":"1999","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_3","first-page":"21","article-title":"Lipoatrophy Associated with Daily Growth Hormone Injections","volume":"2021","author":"Chhiba","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1515\/JPEM.1995.8.4.243","article-title":"Adverse Events During Growth Hormone Therapy","volume":"8","author":"Cowell","year":"1995","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc07-1739","article-title":"Human Insulin Analog\u2014Induced Lipoatrophy","volume":"31","author":"Lopez","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-09-0422","article-title":"Lipoatrophy in GH Deficient Patients Treated with a Long-Acting Pegylated GH","volume":"161","author":"Touraine","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-013-9904-3","article-title":"The Metabolic Effects of Growth Hormone in Adipose Tissue","volume":"44","author":"Chaves","year":"2013","journal-title":"Endocrine"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ionova, Y., and Wilson, L. (2020). Biologic Excipients: Importance of Clinical Awareness of Inactive Ingredients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235076"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-Acting Growth Hormone Preparations\u2013Current Status and Future Considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0169-409X(02)00021-2","article-title":"The Origin of Pegnology","volume":"54","author":"Davis","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1210\/jc.2010-1931","article-title":"Pegylated Long-Acting Human Growth Hormone Possesses a Promising Once-Weekly Treatment Profile, and Multiple Dosing is Well Tolerated in Adult Patients with Growth Hormone Deficiency","volume":"96","author":"Sondergaard","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","first-page":"157","article-title":"The 20-kD Human Growth Hormone Reduces Body Fat by Increasing Lipolysis and Decreasing Lipoprotein Lipase Activity","volume":"58","author":"Takahashi","year":"2002","journal-title":"Horm. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1438723","DOI":"10.1155\/2019\/1438723","article-title":"Use of PEGylated Recombinant Human Growth Hormone in Chinese Children with Growth Hormone Deficiency: A 24-Month Follow-Up Study","volume":"2019","author":"Qiao","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhu, J., Yuan, K., Rana, S., Jakki, S.L., Bhat, A.S., Liang, L., and Wang, C. (2024). Long-Acting Growth Hormone in the Treatment of Growth Hormone Deficiency in Children: A Systematic Literature Review and Network Meta-Analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-58616-4"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1210\/clinem\/dgad183","article-title":"Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment\/Disease Burden Results From REAL 3","volume":"108","author":"Battelino","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11102-024-01440-w","article-title":"Somapacitan-Induced Reversible Lipoatrophy in An Adult Woman with Hypopituitarism","volume":"27","author":"Rakusa","year":"2024","journal-title":"Pituitary"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/acs.molpharmaceut.5b00868","article-title":"In Vitro and In Vivo Characterization of MOD-4023, A Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone","volume":"13","author":"Hershkovitz","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","article-title":"Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study","volume":"107","author":"Deal","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/jpem-2022-0359","article-title":"An Open-Label Extension of a Phase 2 Dose-Finding Study of Once-Weekly Somatrogon vs. Once-Daily Genotropin in Children with Short Stature Due to Growth Hormone Deficiency: Results Following 5 Years of Treatment","volume":"36","author":"Zadik","year":"2023","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4274\/jcrpe.2183","article-title":"Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children","volume":"7","author":"Neyzi","year":"2015","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.0105-1873.2006.0866g.x","article-title":"Severe Adverse Cutaneous Reaction to Insulin Due to Cresol Sensitivity","volume":"55","author":"Rajpar","year":"2006","journal-title":"Contact Dermat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Terzi, A., Yazidi, M., Grassa, A., Khessairi, N., Grira, W., Oueslati, I., and Chihaoui, M. (2022, January 21\u201324). Effective Treatment of Allergy to the Insulin Excipient Meta-Cresol with Desensitization Therapy in Type 1 Diabetes Mellitus: A Case Report. Proceedings of the European Congress of Endocrinology 2022, Milan, Italy.","DOI":"10.1530\/endoabs.81.EP527"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/1\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:23:01Z","timestamp":1759918981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/1\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["children12010058"],"URL":"https:\/\/doi.org\/10.3390\/children12010058","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]}}}